SecBot SecBot
PRESS-RELEASE ·Filed Sep 10, 2026

TEVA

Teva Pharmaceutical Industries Ltd
NEUTRAL
Impact 5/10
Horizonweeks Processed2mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight • Neutral

The refinancing is credit-positive for bondholders but neutral for equity, monitor the Q3 2026 earnings for actual interest expense savings and leverage ratio improvement. The 424B5 cross-filing from 2 days ago previewed this; the pricing confirmation removes uncertainty. No immediate equity catalyst.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$36.35
T+0 close · Sep 10, 2026 · via day close
Latest settled
+7.98%
T+20 · $39.25 · next T+60 in 17d
Vs SPY
+5.85%
α at T+20
Latest observation
+24.38%
T+45 · FF3 residual α
  1. T+0 · Sep 10 $36.35entry
  2. T+1 · 2mo ago +2.04%α +1.18% · $37.09
  3. T+5 · 2mo ago +7.81%α +8.31% · $39.19
  4. T+20 · 6w ago +7.98%α +5.85% · $39.25
  5. T+47 · todayOpen
  6. T+60 · in 17d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Teva priced a ~$4.9B multi-tranche senior notes offering across five maturities (2032-2037), with proceeds to fund the conditional redemption of up to ~$4.5B in higher-coupon debt (6.750% 2028s, 7.875% 2029s, 7.375% 2029s, plus portions of 4.750% 2027s and 4.375% 2030s). This liability management refinancing reduces near-term interest costs and extends maturities, a credit-positive move for bondholders but neutral for equity holders as it does not alter the fundamental business outlook or leverage trajectory beyond the refinancing math. The cross-filing 424B5 from 2 days ago previewed this offering; the pricing confirmation removes uncertainty on size and coupon rates, with settlement expected September 16, 2026.

Key Financial Metrics

Deal Value
$4.9B

Key Facts

  • Offering sized at ~$4.9B equivalent across five tranches: €1B 4.250% 2033, €500M 4.625% 2036, $1B 5.500% 2034, $1B 5.750% 2037, $1.2B 5.250% 2032.
  • Proceeds to fund conditional redemption of up to ~$4.5B in higher-coupon notes (6.750% 2028s, 7.875% 2029s, 7.375% 2029s, 4.750% 2027s, 4.375% 2030s).
  • Additional notice to redeem all 8.125% 2031 notes and reduce 4.375% 2030 redemption from €1.25B to €1.15B expected on Sept 10, 2026.
  • Settlement expected on or about September 16, 2026.
  • Notes are unsecured senior obligations guaranteed by Teva.

Financial Impact

~$4.9B new debt issuance to refinance ~$4.5B of higher-coupon debt, reducing annual interest expense by an estimated ~$100-150M based on coupon differentials (e.g., 6.750% vs 5.250% on USD tranches).

interest expensedebt maturity profileleverage

Risk Factors

  • Execution risk on conditional redemptions if settlement conditions are not met.
  • Higher absolute debt load (~$4.9B) despite lower coupons; leverage remains elevated.
  • Potential for additional redemptions or amendments per Teva's discretion, creating uncertainty for bondholders of remaining notes.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3359281

Track record

61 reports on TEVA

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 15 of 17 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
  2. Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
  3. Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
  5. Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
  6. Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
  7. Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
  8. Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
  9. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
  10. Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
Showing 10 of 61

US Market Status

Market Closed · Opens Wed (11h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 10, 2026